Literature DB >> 11279519

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.

P Kuehl1, J Zhang, Y Lin, J Lamba, M Assem, J Schuetz, P B Watkins, A Daly, S A Wrighton, S D Hall, P Maurel, M Relling, C Brimer, K Yasuda, R Venkataramanan, S Strom, K Thummel, M S Boguski, E Schuetz.   

Abstract

Variation in the CYP3A enzymes, which act in drug metabolism, influences circulating steroid levels and responses to half of all oxidatively metabolized drugs. CYP3A activity is the sum activity of the family of CYP3A genes, including CYP3A5, which is polymorphically expressed at high levels in a minority of Americans of European descent and Europeans (hereafter collectively referred to as 'Caucasians'). Only people with at least one CYP3A5*1 allele express large amounts of CYP3A5. Our findings show that single-nucleotide polymorphisms (SNPs) in CYP3A5*3 and CYP3A5*6 that cause alternative splicing and protein truncation result in the absence of CYP3A5 from tissues of some people. CYP3A5 was more frequently expressed in livers of African Americans (60%) than in those of Caucasians (33%). Because CYP3A5 represents at least 50% of the total hepatic CYP3A content in people polymorphically expressing CYP3A5, CYP3A5 may be the most important genetic contributor to interindividual and interracial differences in CYP3A-dependent drug clearance and in responses to many medicines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11279519     DOI: 10.1038/86882

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  476 in total

1.  Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.

Authors:  Nayoung Han; Hwi-yeol Yun; Jin-yi Hong; In-Wha Kim; Eunhee Ji; Su Hyun Hong; Yon Su Kim; Jongwon Ha; Wan Gyoon Shin; Jung Mi Oh
Journal:  Eur J Clin Pharmacol       Date:  2012-06-02       Impact factor: 2.953

Review 2.  Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

3.  PharmGKB summary: very important pharmacogene information for CYP3A5.

Authors:  Jatinder Lamba; Joan M Hebert; Erin G Schuetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2012-07       Impact factor: 2.089

Review 4.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

5.  CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations.

Authors:  C Balram; Qingyu Zhou; Yin Bun Cheung; Edmund J D Lee
Journal:  Eur J Clin Pharmacol       Date:  2003-05-17       Impact factor: 2.953

6.  Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.

Authors:  R M Savic; A Barrail-Tran; X Duval; G Nembot; X Panhard; D Descamps; C Verstuyft; B Vrijens; A-M Taburet; C Goujard; F Mentré
Journal:  Clin Pharmacol Ther       Date:  2012-10-03       Impact factor: 6.875

7.  One Standardized Differentiation Procedure Robustly Generates Homogenous Hepatocyte Cultures Displaying Metabolic Diversity from a Large Panel of Human Pluripotent Stem Cells.

Authors:  Annika Asplund; Arvind Pradip; Mariska van Giezen; Anders Aspegren; Helena Choukair; Marie Rehnström; Susanna Jacobsson; Nidal Ghosheh; Dorra El Hajjam; Sandra Holmgren; Susanna Larsson; Jörg Benecke; Mariela Butron; Annelie Wigander; Karin Noaksson; Peter Sartipy; Petter Björquist; Josefina Edsbagge; Barbara Küppers-Munther
Journal:  Stem Cell Rev Rep       Date:  2016-02       Impact factor: 5.739

8.  Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

Authors:  Corine Ekhart; Valerie D Doodeman; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

9.  Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach.

Authors:  Cécile Gérard; Jeanick Stocco; Anne Hulin; Benoit Blanchet; Céline Verstuyft; François Durand; Filomena Conti; Christophe Duvoux; Michel Tod
Journal:  AAPS J       Date:  2014-02-14       Impact factor: 4.009

10.  Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers.

Authors:  Jing-Jing Zhang; Hua Zhang; Xiao-Liang Ding; Sheng Ma; Li-Yan Miao
Journal:  Eur J Clin Pharmacol       Date:  2012-10-25       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.